Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
UCN-01 (7-hydroxy-staurosporine) is a potent and selective inhibitor of protein kinase C (PKC), one of several protein kinases examined. UCN-01 itself was shown to exhibit antitumor activity in vitro and in vivo in oncogene-activated human and murine tumor cell lines. Since the mechanism(s) of action of UCN-01 is thought to be different from those of alkylating agents, including mitomycin C (MMC), we tested the combined effect of UCN-01 with MMC on human epidermoid carcinoma A431 cells. UCN-01 potentiated the antiproliferative activity of MMC and yet it did not affect the growth of the cells in vitro. However, other nonselective protein kinase inhibitors, such as staurosporine, K-252a, KT6124 (a derivative of K-252a) and H7, did not enhance the activity of MMC. Isobologram analysis revealed that the interaction of UCN-01 with MMC was synergistic in its antiproliferative activity. A DNA histogram of A431 cells treated with both UCN-01 and MMC showed a block in the cell cycle at the G1/S phase. However, a histogram of cells treated with UCN-01 or MMC alone showed a G1 or a G2M block, respectively. The combined effect of UCN-01 with MMC was further examined in vivo in xenografted A431 cells in nude mice. The combination of both drugs in a single i.v. injection exhibited greater antitumor activity than MMC and UCN-01 alone (P < 0.01). This synergistic antitumor effect was also confirmed in two other solid tumor cell lines, i.e. human xenografted colon carcinoma Co-3 and murine sarcoma 180. The same was observed in the i.v.-inoculated P388 leukemia model, in which we saw an increased lifespan of mice when UCN-01 was combined with MMC. These results suggests the feasibility of using UCN-01 in clinical oncology, especially in combination with alkylating agents such as MMC. In addition, this combination therapy might be a novel chemotherapeutic approach to MMC-insensitive tumors in clinical trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have shown that UCN-01 abrogates Chk1-dependent cellular responses and sensitizes cancer cells to several DNA damaging agents, including mitomycin C (Akinaga et al., 1993), cisplatin (Bunch and Eastman, 1996), camptothecin (Shao et al., 1997), and 5-fluorouracil (Hsueh et al., 1998).”
From ATR–Chk1 Pathway Inhibition Promotes Apoptosis after UV Treatment in Primary Human Keratinocytes: Potential Basis for the UV Protective Effects of Caffeine (2009) · cites this paper as Akinaga et al., 1993
Citations
Cites
Hidaka, H., Inagaki, M., Kawamoto, S., & Sasaki, Y. (1984) · Biochemistry · doi:10.1021/bi00316a032 · Cited by 2,687
Staurosporine, a potent inhibitor of phospholipidCa++dependent protein kinase
Tamaoki, T., Nomoto, H., Takahashi, I., Kato, Y., Morimoto, M., & Tomita, F. (1986) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(86)90008-2 · Cited by 2,452
Giard, D. J., Aaronson, S. A., Todaro, G. J., Arnstein, P., Kersey, J. H., Dosik, H., & Parks, W. P. (1973) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/51.5.1417 · Cited by 2,289
Berenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414
Kase, H., Iwahashi, K., Nakanishi, S., Matsuda, Y., Yamada, K., Takahashi, M., Murakata, C., Sato, A., & Kaneko, M. (1987) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(87)90293-2 · Cited by 938
Isolation and Structure of a Covalent Cross-Link Adduct Between Mitomycin C and DNA
Tomasz, M., Lipman, R., Chowdary, D., Pawlak, J., Verdine, G. L., & Nakanishi, K. (1987) · Science · doi:10.1126/science.3103215 · Cited by 452
Phorbol esters induce multidrug resistance in human breast cancer cells.
Fine, R. L., Patel, J., & Chabner, B. A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.2.582 · Cited by 238
Akinaga, S., Gomi, K., Morimoto, M., Tamaoki, T., & Okabe, M. (1991) · PubMed · Cited by 189
Self-citationTAKAHASHI, I., SAITOH, Y., YOSHIDA, M., SANO, H., NAKANO, H., MORIMOTO, M., & TAMAOKI, T. (1989) · The Journal of Antibiotics · doi:10.7164/antibiotics.42.571 · Cited by 155
Yu, G., Ahmad, S., Aquino, A., Fairchild, C. R., Trepel, J. B., Ohno, S., Suzuki, K., Tsuruo, T., Cowan, K. H., & Glazer, R. I. (1991) · Cancer Communications · doi:10.3727/095535491820873263 · Cited by 143
Research works printed but not linked: 2
- Bush JA, Long BH, Catino JJ, Brander WT, Tomita K (1987) Production and biological activities of rebeccmycin, a novel antitumor agent. J Antibiot 40: 666
- Geran RI, Greenberg NH, MacDonald MM, Schumacher AM, Abbot BJ (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological activities. Cancer Chemother Rep 3: 1
Cited by
Preclinical and Clinical Development of Cyclin-Dependent Kinase Modulators
Senderowicz, A. M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.5.376 · Cited by 492
UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53
Wang, Q., Fan, S., Eastman, A., Worland, P. J., Sausville, E. A., & O'Connor, P. M. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.14.956 · Cited by 453
Targeting the checkpoint kinases: chemosensitization versus chemoprotection
Zhou, B.-B. S., & Bartek, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1296 · Cited by 391
Cyclin-Dependent Kinase Inhibitors: Useful Targets in Cell Cycle Regulation
Sielecki, T. M., Boylan, J. F., Benfield, P. A., & Trainor, G. L. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990256j · Cited by 323
Small-molecule cyclin-dependent kinase modulators
Senderowicz, A. M. (2003) · Oncogene · doi:10.1038/sj.onc.1206954 · Cited by 236
Jackson, J. R., Gilmartin, A. G., Imburgia, C. S., Winkler, J. D., Marshall, L. A., & Roshak, A. (2000) · PubMed · Cited by 255
(1996) · PubMed · Cited by 221
Fuse, E., Tanii, H., Kurata, N., Kobayashi, H., Shimada, Y., Tamura, T., Sasaki, Y., Tanigawara, Y., Lush, R. D., Headlee, D. J., et al. (1998) · PubMed · Cited by 229
Self-citationGranville, C. A., Memmott, R. M., Gills, J. J., & Dennis, P. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1654 · Cited by 181
Cell cycle checkpoints and their impact on anticancer therapeutic strategies
Eastman, A. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10699 · Cited by 159
Dai, Y., Yu, C., Singh, V., Tang, L., Wang, Z., McInistry, R., Dent, P., & Grant, S. (2001) · PubMed · Cited by 176
Targeting Checkpoint Kinase 1 in Cancer Therapeutics
Tse, A. N., Carvajal, R. D., & Schwartz, G. K. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2793 · Cited by 166
Classical PKC isoforms in cancer
Martiny‐Baron, G., & Fabbro, D. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.04.001 · Cited by 139
Kohn, E. A., Yoo, C. J., & Eastman, A. R. (2003) · PubMed · Cited by 138
Small molecule modulators of cyclin-dependent kinases for cancer therapy
Senderowicz, A. M. (2000) · Oncogene · doi:10.1038/sj.onc.1204085 · Cited by 132
Review of UCN‐01 Development: A Lesson in the Importance of Clinical Pharmacology
Fuse, E., Kuwabara, T., Sparreboom, A., Sausville, E. A., & Figg, W. D. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005274549 · Cited by 110
Kortmansky, J. S., Shah, M. A., Kaubisch, A., Weyerbacher, A. R., Yi, S., Tong, W. P., Sowers, R. S., Gönen, M., O'Reilly, E. M., Kemeny, N. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.116 · Cited by 123
Staurosporine analogues — pharmacological toys or useful antitumour agents?
Gescher, A. J. (2000) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00058-5 · Cited by 118
Yu, L., Orlandi, L., Wang, P., Orr, M. S., Senderowicz, A. M., Sausville, E. A., Silvestrini, R., Watanabe, N., Piwnica-Worms, H., & O'Connor, P. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.50.33455 · Cited by 98
Lara, P. N., Mack, P. C., Synold, T. W., Frankel, P. H., Longmate, J., Gumerlock, P. H., Doroshow, J. H., & Gandara, D. R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2602 · Cited by 100
Heffernan, T. P., Kawasumi, M., Blasina, A., Anderes, K., Conney, A. H., & Nghiem, P. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.435 · Cited by 95
“Studies have shown that UCN-01 abrogates Chk1-dependent cellular responses and sensitizes cancer cells to several DNAdamaging agents, including mitomycin C (Akinaga et al., 1993), cisplatin (Bunch and Eastman, 1996), camptothecin (Shao et al.”
BackgroundSenderowicz, A. M. (2001) · Leukemia · doi:10.1038/sj.leu.2401994 · Cited by 100
Gescher, A. J. (1998) · General Pharmacology The Vascular System · doi:10.1016/s0306-3623(98)00069-x · Cited by 103
Akinaga, S., Nomura, K., Gomi, K., & Okabe, M. (1994) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685899 · Cited by 91
Self-citationSugiyama, K., Shimizu, M., Akiyama, T., Tamaoki, T., Yamaguchi, K., Takahashi, R., Eastman, A. R., & Akinaga, S. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000301)85:5<703::aid-ijc17>3.0.co;2-7 · Cited by 89
Self-citationSignal Transduction–Directed Cancer Treatments
Sausville, E. A., Elsayed, Y. A., Monga, M., & Kim, G. (2003) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.135813 · Cited by 96
Endothelial Cell Layer Subjected to Impinging Flow Mimicking the Apex of an Arterial Bifurcation
Szymanski, M. P., Metaxa, E., Meng, H., & Kolega, J. J. (2008) · Annals of Biomedical Engineering · doi:10.1007/s10439-008-9540-x · Cited by 86
Therapeutic Exploitation of Checkpoint Defects in Cancer Cells Lacking p53 Function
Dixon, H., & Norbury, C. J. (2002) · Cell Cycle · doi:10.4161/cc.1.6.257 · Cited by 100
Shao, R., Shimizu, T., & Pommier, Y. G. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3650 · Cited by 85
Protein Kinase C Targeting in Antineoplastic Treatment Strategies
Jarvis, W. D., & Grant, S. (1999) · Investigational New Drugs · doi:10.1023/a:1006328303451 · Cited by 84
Jia, W., Yu, C., Rahmani, M., Krystal, G. W., Sausville, E. A., Dent, P., & Grant, S. (2003) · Blood · doi:10.1182/blood-2002-12-3785 · Cited by 84
Senderowicz, A. M. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0624-x · Cited by 84
Cyclin-dependent kinase inhibitors: novel anticancer agents
Mani, S., Wang, C., Wu, K., Francis, R., & Pestell, R. G. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.8.1849 · Cited by 86
UCN‐01, an anti‐tumor drug, is a selective inhibitor of the conventional PKC subfamily
Mizuno, K., Nöda, K., Ueda, Y., Hanaki, H., Saido, T. C., Ikuta, T., Kuroki, T., Tamaoki, T., Hirai, S.-I., Osada, S., et al. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00042-8 · Cited by 77
Modulation of protein kinase C in antitumor treatment
Hofmann, J. (2008) · Springer eBooks · doi:10.1007/bfb0117491 · Cited by 79
UCN-01 Enhances the In Vitro Toxicity of Clinical Agents in Human Tumor Cell Lines
Monks, A. P., Harris, E. D., Vaigro-Wolff, A., Hose, C. D., Connelly, J. W., & Sausville, E. A. (2000) · Investigational New Drugs · doi:10.1023/a:1006313611677 · Cited by 79
Pollack, I. F., Kawecki, S., & Lazo, J. S. (1996) · Journal of neurosurgery · doi:10.3171/jns.1996.84.6.1024 · Cited by 73
Fuse, E., Tanii, H., TAKAI, K., Asanome, K., Kurata, N., Kobayashi, H., Kuwabara, T., Kobayashi, S., & Sugiyama, Y. (1999) · PubMed · Cited by 72
Sampath, D., Shi, Z., & Plunkett, W. K. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.3.680 · Cited by 76
Dees, E. C., Baker, S. D., O’Reilly, S., Rudek, M. A., Davidson, S. B., Aylesworth, C. A., Elza-Brown, K., Carducci, M. A., & Donehower, R. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.664.11.2 · Cited by 75
Shao, R., Cao, C., & Pommier, Y. G. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31321 · Cited by 65
New opportunities in chemosensitization and radiosensitization: modulating the DNA-damage response
Luo, Y., & Leverson, J. D. (2005) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.5.2.333 · Cited by 66
Hahn, M., Li, W., Yu, C., Rahmani, M., Dent, P., & Grant, S. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0137 · Cited by 63
Wilsker, D., & Bunz, F. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0679 · Cited by 57
Grant, S., & Roberts, J. D. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00141-3 · Cited by 63
Bredel, M., & Pollack, I. F. (1997) · Acta Neurochirurgica · doi:10.1007/bf01411552 · Cited by 55
Signalling pathways as target for anticancer drug development
Powis, G. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90005-1 · Cited by 54
Inhibitors of cyclin-dependent kinase modulators for cancer therapy
Senderowicz, A. M. (2006) · Birkhäuser-Verlag eBooks · doi:10.1007/3-7643-7414-4_8 · Cited by 61
Metabolism Studies of Indole Derivatives Using a Staurosporine Producer,Streptomyces staurosporeus
Yang, S., & Cordell, G. A. (1997) · Journal of Natural Products · doi:10.1021/np960566u · Cited by 51
Eastman, A. R., Kohn, E. A., Brown, M. K., Rathman, J., Livingstone, M., Blank, D. H. A., & Gribble, G. W. (2002) · PubMed · Cited by 46
RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma.
Mack, P. C., Gandara, D. R., Bowen, C., Edelman, M. J., Paglieroni, T. G., Schnier, J. B., Gelmann, E. P., & Gumerlock, P. H. (1999) · PubMed · Cited by 48
Wu, G., Xu, L., Lin, N., & Liu, B. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-167 · Cited by 46
Targeting DNA repair and the cell cycle in glioblastoma
Alexander, B. M., Pinnell, N. E., Wen, P. Y., & D’Andrea, A. D. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0765-4 · Cited by 40
Tsuchida, E., & Urano, M. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)00549-x · Cited by 38
Schupp, P. J., Steube, K. G., Meyer, C., & Proksch, P. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00694-2 · Cited by 38
Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma
Mack, P. C., Gandara, D. R., Lau, A. H., Lara, P. N., Edelman, M. J., & Gumerlock, P. H. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0571-6 · Cited by 38
Sugiyama, K., Akiyama, T., Shimizu, M., Tamaoki, T., Courage, C., Gescher, A. J., & Akinaga, S. (1999) · PubMed · Cited by 37
Self-citationA phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas
Kummar, S., Gutierrez, M. E., Gardner, E. R., Figg, W. D., Melillo, G., Dancey, J. E., Sausville, E. A., Conley, B. A., Murgo, A. J., & Doroshow, J. H. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1154-y · Cited by 36
Functions and inhibitors of CHK1 in cancer therapy
Jiang, K., Deng, M., Du, W., Liu, T., Li, J., & Zhou, Y. (2024) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2024.100185 · Cited by 35
Rong-Guangshao, Chun-XiaCAO, & YvesPOMMIER (2004) · PubMed · Cited by 35
Wilson, W. H., Sorbara, L. R., Figg, W. D., Mont, E. K., Sausville, E. A., Warren, K. E., Balis, F. M., Bauer, K. D., Raffeld, M. A., Senderowicz, A. M., et al. (2000) · PubMed · Cited by 32
Playle, L. C., Hicks, D. J., Qualtrough, D., & Paraskeva, C. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600492 · Cited by 36
The Adaptive Mechanisms and Checkpoint Responses to a Stressed DNA Replication Fork
Saldanha, J., Rageul, J., Patel, J. A., & Kim, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310488 · Cited by 30
Bhonde, M., Hanski, M., Magrini, R., Moorthy, N. D., Müller, A., Sausville, E. A., Kohno, K., Wiegand, P., Daniel, P. T., Zeitz, M., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207842 · Cited by 28
Martin, D. S., Stolfi, R. L., & Colofiore, J. R. (1997) · Cancer Investigation · doi:10.3109/07357909709039742 · Cited by 27
Ichikawa, S., Tatebayashi, N., & Matsuda, A. (2013) · The Journal of Organic Chemistry · doi:10.1021/jo4020672 · Cited by 25
Fuse, E., Hashimoto, A., Sato, N., Tanii, H., Kuwabara, T., Kobayashi, S., & Sugiyama, Y. (2000) · Pharmaceutical Research · doi:10.1023/a:1007512832006 · Cited by 25
Katsuki, M., Chuang, V. T. G., Nishi, K., Kawahara, K., Nakayama, H., Yamaotsu, N., Hirono, S., & Otagiri, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m411076200 · Cited by 25
Yamauchi, T., Keating, M. J., & Plunkett, W. K. (2002) · PubMed · Cited by 25
Akiyama, T., Sugiyama, K., Shimizu, M., Tamaoki, T., & Akinaga, S. (1999) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1999.tb00721.x · Cited by 24
Self-citationHarvey, S., Decker, R., Dai, Y., Schaefer, G., Tang, L., Kramer, L. B., Dent, P., & Grant, S. (2001) · PubMed · Cited by 24
Glucose-dependent regulation of pregnane X receptor is modulated by AMP-activated protein kinase
Oladimeji, P. O., Lin, W., Brewer, C., & Chen, T. (2017) · Scientific Reports · doi:10.1038/srep46751 · Cited by 23
Cell Cycle Modulators for the Treatment of Lung Malignancies
Senderowicz, A. M. (2003) · Clinical Lung Cancer · doi:10.3816/clc.2003.n.028 · Cited by 24
Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01
Kurata, N., Kuwabara, T., Tanii, H., Fuse, E., Akiyama, T., Akinaga, S., Kobayashi, H., Yamaguchi, K., & Kobayashi, S. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050939 · Cited by 24
Self-citationO- andN-Methylation in the Biosynthesis of Staurosporine
Yang, S., Lin, L.-J., Cordell, G. A., Wang, P., & Corley, D. G. (1999) · Journal of Natural Products · doi:10.1021/np990261q · Cited by 21
New Chemotherapeutic Agents for the Treatment of Non-small Cell Lung Cancer
Saijo, N. (1998) · CHEST Journal · doi:10.1378/chest.113.1_supplement.17s · Cited by 20
Enhancement of radiotherapeutic effectiveness by temperature-sensitive liposomal 1-methylxanthine
Jeong, S., Yi, S. L., Lim, S.-K., Park, S. J., Jung, J., Woo, H., Song, S. Y., Kim, J.-S., Lee, J. S., Lee, J., et al. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.12.040 · Cited by 21
DNA damage response and development of targeted cancer treatments
Gasser, S. (2007) · Annals of Medicine · doi:10.1080/07853890701436773 · Cited by 18
Biosynthesis of Staurosporine: Incorporation of Glucose
Yang, S., & Cordell, G. A. (1996) · Journal of Natural Products · doi:10.1021/np960109d · Cited by 18
Xiao, H. H., Makeyev, Y., Butler, J. T., Vikram, B., & Franklin, W. A. (2002) · Radiation Research · doi:10.1667/0033-7587(2002)158[0084:hupscw]2.0.co;2 · Cited by 18
Jane, E. P., Premkumar, D. R., & Pollack, I. F. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.06.020 · Cited by 18
Kruger, E. A., & Figg, W. D. (2001) · PubMed · Cited by 17
Koh, J., Kubota, T., Migita, T., Abe, S., Hashimoto, M., HOSODA, Y., & Kitajima, M. (2002) · Breast Cancer · doi:10.1007/bf02967547 · Cited by 16
Yang, S., & Cordell, G. A. (1997) · Journal of Natural Products · doi:10.1021/np960674g · Cited by 16
Cyclin-dependent kinases as new targets for the prevention and treatment of cancer
Senderowicz, A. M. (2002) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(02)00049-7 · Cited by 21
Origin of Nitrogen in the Indolocarbazole Unit of Staurosporine
Yang, S., & Cordell, G. A. (1997) · Journal of Natural Products · doi:10.1021/np970192k · Cited by 15
Murray, M. M., Terry, N. H. A., & Keyomarsi, K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1809 · Cited by 16
Enhancement of Radiation Cytotoxicity by UCN-01 in Non-small Cell Lung Carcinoma Cells
Mack, P. C., Jones, A. A., Gustafsson, M. H., Gandara, D. R., Gumerlock, P. H., & Goldberg, Z. (2004) · Radiation Research · doi:10.1667/rr3253 · Cited by 19
Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors
Wang, W. T., Catto, J. W. F., & Meuth, M. (2014) · Oncogene · doi:10.1038/onc.2014.221 · Cited by 14
Abe, S., Kubota, T., Otani, Y., Furukawa, T., Watanabe, M., Kumai, K., & Kitajima, M. (2000) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2000.tb00904.x · Cited by 15
Recent developments in protein kinase C inhibitors
Harris, W. R., Wilkinson, S., & Nixon, J. (1997) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.7.1.63 · Cited by 13
Otsubo, A., BHAWAL, U. K., Nomura, Y., Mitani, Y., Ozawa, K., Kuniyasu, H., & Sugiyama, M. (2006) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2005.11.022 · Cited by 12
Recent Advances in the Development of Anticancer Drugs that Act against Signalling Pathways
Powis, G. (1994) · Tumori Journal · doi:10.1177/030089169408000201 · Cited by 12
NOVEL TARGETS IN THE CELL CYCLE AND CELL CYCLE CHECKPOINTS
Pommier, Y. G., Yu, Q., & Kohn, K. W. (2002) · Elsevier eBooks · doi:10.1016/b978-012072651-6/50003-6 · Cited by 12
Sako, Y., Ichikawa, S., Osada, A., & Matsuda, A. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.09.042 · Cited by 10
Deuterium Labeling and Mass Fragmentation Studies of Staurosporine
Yang, S., & Cordell, G. A. (1997) · Journal of Natural Products · doi:10.1021/np960567m · Cited by 9
Koh, J., Kubota, T., Koyama, T., Migita, T., Hashimoto, M., HOSODA, Y., & Kitajima, M. (2003) · Breast Cancer · doi:10.1007/bf02966727 · Cited by 10
Edrada‐Ebel, R., Wray, V., Handayani, D., Schupp, P. J., Oliveros, M. B., & Proksch, P. (2000) · Studies in natural products chemistry · doi:10.1016/s1572-5995(00)80008-3 · Cited by 8
Schwartz, G. K. (1996) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.5.12.1601 · Cited by 8
Protein kinase C as a target for new anti-cancer agents
van Gijn, R., Zuidema, X., Bult, A., & Beijnen, J. H. (1999) · Journal of Oncology Pharmacy Practice · doi:10.1177/107815529900500402 · Cited by 7
Metadata
- Authors
- Akinaga, S., Nomura, K., Gomi, K., & Okabe, M.
- ORCID
- Nomura, Kayo
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 1993
- Volume
- 32
- Issue
- 3
- Pages
- 183-189
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2078730133
- Cited by
- 118
- References
- 22
- Citations by year
- 2024: 1 · 2023: 1 · 2018: 1 · 2017: 1 · 2014: 1 · 2013: 3 · 2012: 1
- FWCI
- 1.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Chemotherapy and Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- UCN-01, mitomycin C, protein kinase C inhibition, combination chemotherapy, synergistic antitumor effect, alkylating agents, staurosporine, K252a, tumor xenografts, P388 leukemia
- MeSH terms
- Alkaloids, Animals, Antineoplastic Combined Chemotherapy Protocols, Cell Cycle, Cell Division, Drug Synergism, Male, Mice, Inbred BALB C, Mice, Inbred DBA, Mice, Inbred Strains, Mice, Nude, Neoplasm Transplantation, Neoplasms, Experimental, Protein Kinase C, Tumor Cells, Cultured, Mitomycin, Staurosporine, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.